KLOR-Con/EF 978 mg/1

Potassium Bicarbonate · TABLET, EFFERVESCENT · Upsher-Smith Laboratories, Inc.

No Recall HistoryCurrently in Shortage

Plain English

KLOR-Con/EF is a prescription tablet, effervescent containing potassium bicarbonate at 978 mg/1, taken oral. Manufactured by Upsher-Smith Laboratories, Inc..

Key Facts

Brand Name: KLOR-Con/EF
Generic Name: Potassium Bicarbonate
NDC Code (Product): 0245-5326
Manufacturer: Upsher-Smith Laboratories, Inc.
Strength: 978 mg/1
Dosage Form: TABLET, EFFERVESCENT
Route: ORAL
Marketing Status: HUMAN PRESCRIPTION DRUG
Drug Class: Increased Large Intestinal Motility [PE]; Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]
Marketing Start: 09/01/2014

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

diarrhoea64 reports

off label use53 reports

acute kidney injury43 reports

dyspnoea42 reports

fatigue42 reports

pain41 reports

pneumonia39 reports

vomiting38 reports

asthenia37 reports

back pain37 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

INDICATIONS AND USAGE For the treatment of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop (e.g., digitalized patients or patients with significant cardiac arrhythmias). The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated.

Dosage & Administration

DOSAGE AND ADMINISTRATION The usual dietary potassium intake by the average adult is 50 to 100 mEq per day. Potassium depletion sufficient to cause hypokalemia usually requires the loss of 200 mEq or more of potassium from the total body store. Dosage must be adjusted to the individual needs of each patient. The dose for the prevention of hypokalemia is typically 25 mEq per day. Doses of 50 to 100 mEq per day or more are used for the treatment of potassium depletion. Dosage should be divided if more than 25 mEq per day is given such that no more than 25 mEq is given in a single dose. The usual adult dose is 25 to 100 mEq of potassium per day (one KLOR-CON ® /EF tablet 1 to 4 times daily after meals). Each KLOR-CON ® /EF tablet should be dissolved in at least 4 ounces of cold or ice water. These preparations, like other potassium supplements, must be properly diluted to avoid the possibility of gastrointestinal irritation.

Warnings

WARNINGS Hyperkalemia [see OVERDOSAGE ] In patients with impaired mechanisms for excreting potassium, the administration of potassium salts can produce hyperkalemia and cardiac arrest. This occurs most commonly in patients given potassium by the intravenous route but may also occur in patients given potassium orally. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. The use of potassium salts in patients with chronic renal disease, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustment. Interaction with Potassium-Sparing Diuretics Hypokalemia should not be treated by the concomitant administration of potassium salts and a potassium-sparing diuretic (e.g., spironolactone, triamterene or amiloride), since the simultaneous administration of these agents can produce severe hyperkalemia. Interaction with Angiotensin Converting Enzyme Inhibitors Angiotensin converting enzyme (ACE) inhibitors (e.g., captopril, enalapril) will produce some potassium retention by inhibiting aldosterone production. Potassium supplements should be given to patients receiving…

Contraindications

CONTRAINDICATIONS Potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. Hyperkalemia may complicate any of the following conditions: chronic renal failure, systemic acidosis such as diabetic acidosis, acute dehydration, extensive tissue breakdown as in severe burns, adrenal insufficiency or the administration of a potassium-sparing diuretic (e.g., spironolactone, triamterene or amiloride) [see OVERDOSAGE ] .

Drug Interactions

Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors [see WARNINGS ] .

Adverse Reactions

ADVERSE REACTIONS One of the most severe adverse effects is hyperkalemia [see CONTRAINDICATIONS , WARNINGS and OVERDOSAGE ] . The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by diluting the preparation further, taking the dose with meals or reducing the dose.

Frequently Asked Questions

What is KLOR-Con/EF used for?

KLOR-Con/EF contains Potassium Bicarbonate. It is a tablet, effervescent taken oral. Consult your doctor for specific uses.

Is KLOR-Con/EF a controlled substance?

KLOR-Con/EF is not classified as a controlled substance by the DEA.

What is the generic name for KLOR-Con/EF?

The generic name for KLOR-Con/EF is Potassium Bicarbonate. There are 8 other brand versions of Potassium Bicarbonate.

What is the NDC code for KLOR-Con/EF 978 mg/1?

The NDC (National Drug Code) for KLOR-Con/EF 978 mg/1 is 0245-5326, listed by Upsher-Smith Laboratories, Inc..

Product NDC

0245-5326

Package NDC

0245-5326-01

Other Potassium Brands

See all →

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)